Market research
1I4.F HeraMED Limited
F EUR Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 30M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.01
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- AU0000028367
- Market cap
- 30M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.01
About
About HeraMED Limited
HeraMED Limited, a medical data and technology company, develops, manufactures, and sells home-based maternity monitoring technology in Australia and the United States. It provides HeraBEAT, a medical device for fetal and maternal heart rate used by pregnant women; and HeraCARE, a digital maternity and women's health platform that focuses on improving clinical outcomes while supporting more efficient and accessible models of care. The company has a collaboration agreement with Mayo Clinic. HeraMED Limited was founded in 2011 and is based in Hawthorn East, Australia.
Research context
HeraMED Limited appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 1I4.F discussion.
5 years, 6 months ago
HeraMED Limited is currently in a long term uptrend where the price is trading 72.8% above its 200 day moving average.
From a valuation standpoint, the stock is 83.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 219.6.
Finally, its free cash flow fell by 22.0% to $-782K since the same quarter in the previous year.
Based on the above factors, HeraMED Limited gets an overall score of 2/5.